KalVista reports early EKTERLY sales momentum, rising prescriber adoption and global regulatory approvals following the drug's 2025 launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback